Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rinatabart Sesutecan · GEN-1184, PRO-1184

Antibody-drug conjugate · Cytotoxic, directed at folate receptor alpha (FOLR1) · developed by Genmab

Phase 3 Most advanced trial
GMAB Developer
1 Registered trials

What is Rinatabart Sesutecan?

Rinatabart sesutecan is an antibody-drug conjugate that binds folate receptor alpha on tumor cells and, after uptake and linker cleavage, releases the topoisomerase I inhibitor exatecan. It is being studied in platinum-sensitive ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GEN-1184, PRO-1184, Rina-S
Drug type
Antibody-drug conjugate
Targets
folate receptor alpha (FOLR1), topoisomerase I (TOP1) (secondary target)
Mechanism
Cytotoxic, directed at folate receptor alpha (FOLR1)
Pathways
DNA replication inhibition, DNA damage response, apoptosis
Therapy area
Oncology
Developer
Genmab (GMAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
C56LJ7JC3W

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06619236 Phase 3 Platinum-resistant Ovarian Cancer Active not recruiting GMAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian CancerPlatinum-sensitive Ovarian CancerPSOC

Other drugs acting on FOLR1

More from Genmab

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the GMAB page.

Follow GMAB, the company behind Rinatabart Sesutecan

See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GMAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.